Estimated market cap $499.19MShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Oct 7, 2026, last close Nov 13, 2026.42.05M shares, shares as of Oct 7, 2026CIK 1275187The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
0 buys · 3 sells
$654.7K sold, open market
Congress trades, 24 mo
3
1 purchase, 2 sales
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in AngioDynamics, Inc.'s latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What AngioDynamics, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
107
49.3% of shares · 40 added
Latest 10-Q
Q3 2026
What changed in AngioDynamics, Inc.'s latest quarterly report, compared with the one before.
Filed Oct 8, 2026 · Quarter ended Aug 31, 2026
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
AI summary of changes vs the prior report. Written by AI from the paragraphs that changed, and checked against them. This is information, not investment advice.
Compared with the 10-K for the period ended May 31, 2026. Sections compared: risk factors and legal proceedings.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No open-market insider trades reported since Oct 29, 2026. Insiders have two business days to file.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
107 funds report ANGO. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 93% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 38.28M reported shares by 41.33M shares, from the company’s SEC filing as of Jul 10, 2026.
164 funds hold the stock.
Q3 2026: 49% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202591%
Q3 202595%
Q4 202594%
Q1 202694%
Q2 202693%
Q3 2026 (so far)49%
Q3 2026. 21 new, 40 added to, 27 trimmed, 78 exited since Q2 2026.
One of these funds reports its values in thousands of dollars; its figures are shown in dollars.
Download CSVEvery fund that holds ANGO, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
3 in 24 mo
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Recent congressional trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
What AngioDynamics, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q2 2013
82
—
23.68M
$267.1M
Q3 2013
90
+8
23.25M
$307.0M
Q4 2013
105
+15
23.16M
$397.5M
Q1 2014
108
+3
23.03M
$362.7M
Q2 2014
109
+1
26.38M
$430.8M
Q3 2014
105
-4
24.17M
$331.6M
Q4 2014
132
+27
24.87M
$476.7M
Q1 2015
132
0
25.51M
$454.1M
Q2 2015
115
-17
25.23M
$413.7M
Q3 2015
116
+1
24.98M
$329.6M
Q4 2015
120
+4
24.11M
$292.7M
Q1 2016
120
0
24.70M
$303.6M
Q2 2016
119
-1
25.39M
$365.0M
Q3 2016
128
+9
28.04M
$491.7M
Q4 2016
152
+24
31.76M
$548.3M
Q1 2017
163
+11
31.72M
$550.2M
Q2 2017
167
+4
35.60M
$577.0M
Q3 2017
167
0
35.50M
$606.4M
Q4 2017
169
+2
35.87M
$596.6M
Q1 2018
164
-5
36.30M
$626.3M
Q2 2018
174
+10
36.51M
$812.0M
Q3 2018
177
+3
37.93M
$824.5M
Q4 2018
174
-3
38.21M
$769.2M
Q1 2019
179
+5
37.05M
$846.9M
Q2 2019
167
-12
37.21M
$732.7M
Q3 2019
173
+6
37.61M
$692.3M
Q4 2019
157
-16
37.59M
$601.6M
Q1 2020
158
+1
41.75M
$435.5M
Q2 2020
146
-12
36.83M
$374.3M
Q3 2020
138
-8
36.08M
$435.2M
Q4 2020
147
+9
35.81M
$550.4M
Q1 2021
144
-3
37.28M
$881.9M
Q2 2021
161
+17
37.09M
$1.0B
Q3 2021
156
-5
36.57M
$947.7M
Q4 2021
170
+14
36.36M
$1.0B
Q1 2022
144
-26
37.56M
$809.6M
Q2 2022
134
-10
37.33M
$722.4M
Q3 2022
149
+15
37.16M
$759.8M
Q4 2022
149
0
37.15M
$511.6M
Q1 2023
153
+4
36.51M
$377.5M
Q2 2023
156
+3
35.97M
$375.7M
Q3 2023
154
-2
35.39M
$259.0M
Q4 2023
150
-4
38.41M
$300.8M
Q1 2024
135
-15
39.25M
$230.7M
Q2 2024
140
+5
32.97M
$199.5M
Q3 2024
138
-2
32.84M
$255.4M
Q4 2024
135
-3
33.39M
$305.8M
Q1 2025
154
+19
35.45M
$333.3M
Q2 2025
150
-4
36.94M
$366.8M
Q3 2025
146
-4
39.14M
$436.5M
Q4 2025
169
+23
38.92M
$498.2M
Q1 2026
150
-19
38.69M
$439.1M
Q2 2026
164
+14
38.28M
$496.8M
Q3 2026
107
-57
20.72M
$317.8M
Each point is a quarter-end, from Q2 2013 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (03475V101). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2013) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.